Although rastuzumab and other HER2-targeted monoclonal antibodies are effective in treating HER2-positive breast cancer, they can cause cardiotoxicity, HF in particular (Copeland-Halperin et al., 2019). Here, ERBB2 is linked to breast carcinoma.